BF Suma Pharmaceuticals, Inc.: due-diligence report
Public-record summary and buyer worksheet. Records can be incomplete; a listing is not product approval, an audit result or a guarantee of suitability. This report updates as source records change. Print a dated copy to retain the version you reviewed.
Share this report: https://certifiedmanufacturers.com/manufacturers/bf-suma-pharmaceuticals/due-diligence
Profile last verified: Nov 19, 2026. Report printed / reviewed on: ____________________
Certifications and licences
NSF/ANSI 455-2 GMP for Dietary Supplements
Issuer: NSF. Registry status: active. Checked: Nov 19, 2026.
Reference: Not recorded. Expiry: Not recorded.
Scope: Not recorded here; confirm with the registry and manufacturer.
Registry source: https://info.nsf.org/Certified/455GMP/Listings.asp?Facilities
BF Suma Pharmaceuticals, Inc., 5001 Earle Avenue, Rosemead, CA, 91770, US — manufacturing; source: NSF/ANSI 455-2; checked Nov 19, 2026.
BF Suma Pharmaceuticals, Inc., 5077 Walnut Grove Ave, San Gabriel, CA, 91776, US — manufacturing; source: NSF/ANSI 455-2; checked Nov 19, 2026.
FDA inspection history
Dataset date: Oct 28, 2026. Facility records are matched by company and location; confirm that the site is the one in your quote. FDA inspection source.
Apr 22, 2024 — VAI: Voluntary action indicated
BF Suma Pharmaceuticals, Inc., Rosemead, California, United States. FEI: 3006316986; inspection: 1236634.
Food Composition, Standards, Labeling and Econ
21 CFR 111.70(b)(1): Specifications - component identity
21 CFR 111.70(b)(2): Specifications-component purity, strength, composition
21 CFR 111.70(d): Specifications - labels, packaging
Feb 14, 2024 — VAI: Voluntary action indicated
BF Suma Pharmaceuticals, Inc., Rosemead, California, United States. FEI: 3006316986; inspection: 1230617.
Food Composition, Standards, Labeling and Econ
21 CFR 111.70(e): Specifications - identity, purity, strength, composition
21 CFR 111.75(c): Specifications met - verify; finished batch
21 CFR 111.315(d): Standard reference materials; criteria for selecting
FDA recalls
Dataset date: Nov 19, 2026. Recall matches use company names and may concern a different product or facility.
May 8, 2024 — Class II, Terminated
BF Suma Pharmaceuticals, Inc.: Undeclared allergens due to sub-ingredients, soy lecithin and coconut oil
- Longreen Corporation 4 in1 Reishi Coffee, 18.2 grams/sachet, 10 sachets/box
- Longreen Corporation 4 in1 Cordyceps Coffee, 18.2 grams/sachet, 10 sachets/box
- Longreen Corporation Xlim Express Coffee, 15 grams/sachet, 10 sachets/box
Company website claims — not registry verified
Last website check: Unavailable / not checked.
No current website claims available here. Capabilities and commercial terms remain unknown until confirmed with the company.
Evidence to request from the manufacturer
Public records cannot answer these questions. Mark each item after reviewing the evidence. Blank means not assessed, not a failed audit. Notes entered here are not saved or included in a shared URL.
Request role-specific training records and the named quality contact.
21 CFR 111.12Request a site walkthrough, sanitation controls and equipment maintenance records (also §111.25).
21 CFR 111.20Request written identity, purity, strength, composition and contaminant specifications for your product.
21 CFR 111.70Ask how each dietary ingredient is identified and how suppliers and certificates of analysis are qualified.
21 CFR 111.75Request quality control procedures, release authority and handling of deviations and rejected batches.
21 CFR 111.105Request the approved product-specific master manufacturing record and change-control process.
21 CFR 111.205Review a completed batch record with traceability to components, processing and release.
21 CFR 111.255Request scientifically valid test methods, sampling plans and laboratory controls for your specifications.
21 CFR 111.315Request procedures that prevent label mix-ups and control packaging and label reconciliation.
21 CFR 111.403Ask how storage conditions protect identity, purity, strength and composition during holding and distribution.
21 CFR 111.453Request complaint review and investigation procedures; discuss returned-product controls under §111.503.
21 CFR 111.553Confirm retention and access to records supporting your batches.
21 CFR 111.605